Skip to content
OpenCapital
Get started

ADMA Biologics ADMA BIVIGAM — Revenue

Other product segments

ASCENIV
$97.49M+27.7%
Intermediates And Other
$833K-78.5%

Similar metrics at other companies

Iovance Biotherapeutics, Inc. logo
IOVAAmtagvi — Revenue
$60.22M+38.2%
Alkermes logo
ALKSLYBALVI — Revenue
$92.36M+31.9%
Alkermes logo
ALKSVivitrol — Revenue
$112.43M+11.3%
AnaptysBio, Inc. logo
ANABBiopharma Company — Revenue
$0—
LeMaitre Vascular logo
LMATGB — Revenue (Gross)
$3.13M-0.7%
Adaptive Biotechnologies logo
ADPTImmune Medicine Business — Revenue
$3.78M-56.6%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's bivigam — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's BIVIGAM — revenue?
ADMA Biologics (ADMA) reported BIVIGAM — revenue of $15.42M in Q1 2026.
How has ADMA Biologics's BIVIGAM — revenue changed year-over-year?
ADMA Biologics's BIVIGAM — revenue decreased by 54.0% year-over-year, from $33.51M to $15.42M.
What does BIVIGAM — revenue mean?
This metric represents the total gross revenue generated from the sale of the BIVIGAM product line, excluding any taxes collected from customers. It serves as a primary indicator of market demand and commercial adoption for this specific plasma-derived therapeutic. Monitoring this figure helps investors assess the product's contribution to the company's overall top-line growth and its competitive positioning within the immunodeficiency treatment market.